Free Trial
NASDAQ:CYTK

Cytokinetics (CYTK) Stock Price, News & Analysis

Cytokinetics logo
$56.13 -0.03 (-0.05%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$55.58 -0.56 (-0.99%)
As of 11/13/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cytokinetics Stock (NASDAQ:CYTK)

Advanced

Key Stats

Today's Range
$55.15
▼
$56.66
50-Day Range
$53.69
▼
$75.35
52-Week Range
$53.55
▼
$88.31
Volume
1.01 million shs
Average Volume
2.00 million shs
Market Capitalization
$7.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$106.67
Consensus Rating
Moderate Buy

Company Overview

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance.

The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Founded in 1997, Cytokinetics is based in South San Francisco, California. Its research has focused on translating advances in muscle biology into potential treatments for serious cardiovascular and other muscle-related diseases.

AI Generated. May Contain Errors.

Cytokinetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

CYTK MarketRank™: 
3.378360655735 of 5 stars

Cytokinetics scored higher than 68% of companies evaluated by MarketBeat, and ranked 333rd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 19 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Cytokinetics has a consensus price target of $106.67, representing about 90.0% upside from its current price of $56.13.

  • Amount of Analyst Coverage

    Cytokinetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cytokinetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytokinetics are expected to grow in the coming year, from ($5.85) to ($4.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytokinetics is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytokinetics is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    13.21% of the float of Cytokinetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytokinetics has a short interest ratio ("days to cover") of 14.15, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cytokinetics has recently decreased by 3.75%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cytokinetics does not currently pay a dividend.

  • Dividend Growth

    Cytokinetics does not have a long track record of dividend growth.

  • News Sentiment

    Cytokinetics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Cytokinetics this week, compared to 8 articles on an average week.
  • Search Interest

    6 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,208,290.00 in company stock.

  • Percentage Held by Insiders

    2.60% of the stock of Cytokinetics is held by insiders.

  • Percentage Held by Institutions

    Cytokinetics has minimal institutional ownership at this time.

  • Read more about Cytokinetics' insider trading history.
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYTK Stock News Headlines

Truist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK)
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
See More Headlines

CYTK Stock Analysis - Frequently Asked Questions

Cytokinetics' stock was trading at $63.54 at the start of the year. Since then, CYTK stock has decreased by 11.7% and is now trading at $56.13.

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings data on Wednesday, November, 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.06. The company's revenue for the quarter was up 2356.5% on a year-over-year basis.
Read the conference call transcript
.

Cytokinetics' top institutional shareholders include William Blair Investment Management LLC (1.27%), Pictet Asset Management Holding SA (1.10%), GW&K Investment Management LLC (0.73%) and Fisher Asset Management LLC (0.66%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Sung Lee, Andrew Callos, Wendell Wierenga, Wendall Wierenga, Muna Bhanji, Robert Arthur Harrington, Robert Wong, Edward M Md Kaye, Robert E Landry and B Lynne Parshall.
View institutional ownership trends
.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Novavax (NVAX), Tesla (TSLA), Bristol Myers Squibb (BMY), Salesforce (CRM) and Micron Technology (MU).

Company Calendar

Last Earnings
11/04/2026
Today
11/15/2026
UBS Global Biopharma Conference 2026
11/16/2026
Jefferies Global Healthcare Conference
11/17/2026
9th Annual Evercore ISI HealthCONx Conference
11/30/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CYTK
CIK
1061983
Employees
673
Year Founded
1998

Price Target and Rating

High Price Target
$140.00
Low Price Target
$84.00
Potential Upside/Downside
+90.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
21 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$784.96 million
Net Margins
-686.63%
Pretax Margin
-686.63%
Return on Equity
N/A
Return on Assets
-48.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.36
Quick Ratio
3.36

Sales & Book Value

Annual Sales
$88.04 million
Price / Sales
88.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.31) per share
Price / Book
-24.30

Miscellaneous

Outstanding Shares
139,300,000
Free Float
135,681,000
Market Cap
$7.82 billion
Optionable
Optionable
Beta
0.45

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:CYTK) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners